OGN Organon & Co

  1. Stocks
  2. Healthcare
  3. NYSE: OGN

Price (delayed)

$13.395

Market cap

$3.52B

P/E Ratio

14.25

Dividend/share

$0.08

EPS

$0.94

Enterprise value

$10.97B

?
Relative Growth: Rel. Growth: 23
Relative Strength: Rel. Strength: 90
Relative Valuation: Rel. Valuation: 80
Relative Profitability: Rel. Profitability: 62
Highlights
The equity has soared by 67% YoY and by 20% QoQ
The quick ratio has grown by 30% YoY and by 25% from the previous quarter
The company's EPS has shrunk by 68% YoY but it rose by 31% QoQ
Organon's net income has plunged by 67% YoY but it has increased by 32% from the previous quarter
The price to earnings (P/E) is 142% more than the 5-year quarterly average of 5.9 and 123% more than the last 4 quarters average of 6.4
OGN's gross profit is down by 10% year-on-year
Sector: Healthcare
Industry: Drug Manufacturers - General
Peers: OPK ORGO

Key stats

What are the main financial stats of OGN

OGN stock price

How has the Organon stock price performed over time
Intraday
-0.04%
1 week
0.34%
1 month
1.02%
1 year
40.56%
YTD
86.82%
QTD
123.62%

Financial performance

How have Organon's revenue and profit performed over time
Revenue
$6.16B
Gross profit
$3.26B
Operating income
$826M
Net income
$246M
Gross margin
52.8%
Net margin
4%
Organon's net income has plunged by 67% YoY but it has increased by 32% from the previous quarter
Organon's net margin has plunged by 66% YoY but it has increased by 33% from the previous quarter
The company's operating income fell by 33% YoY
OGN's operating margin is down by 32% year-on-year

Price vs fundamentals

How does OGN's price correlate with its fundamentals

Growth

What is Organon's growth rate over time

Valuation

What is Organon stock price valuation
OGN P/E details
P/E
14.25
P/B
3.86
P/S
0.57
EV/EBIT
10.67
EV/EBITDA
7.89
EV/Sales
1.78
The price to earnings (P/E) is 142% more than the 5-year quarterly average of 5.9 and 123% more than the last 4 quarters average of 6.4
The company's EPS has shrunk by 68% YoY but it rose by 31% QoQ
The equity has soared by 67% YoY and by 20% QoQ
The P/B is 43% more than the last 4 quarters average of 2.7
The price to sales (P/S) is 90% higher than the last 4 quarters average of 0.3 but 29% lower than the 5-year quarterly average of 0.8
The revenue has declined by 2.1% year-on-year

Efficiency

How efficient is Organon business performance
The return on equity has dropped by 84% year-on-year but it has grown by 17% since the previous quarter
The ROA has dropped by 68% year-on-year but it is up by 36% since the previous quarter
The return on invested capital has declined by 17% year-on-year but it is up by 11% since the previous quarter
The company's return on sales rose by 12% QoQ but it fell by 11% YoY

Dividends

What is OGN's dividend history
Dividend details
DPS
$0.08
Dividend yield
0.6%
Payout ratio
8.5%
Recent dividends

Special dividends are included in TTM DPS and yield

Financial health

How did Organon financials performed over time
OGN's total assets is 7% more than its total liabilities
The quick ratio has grown by 30% YoY and by 25% from the previous quarter
OGN's current ratio is up by 18% year-on-year and by 8% since the previous quarter
The equity has soared by 67% YoY and by 20% QoQ
The debt to equity has contracted by 43% YoY and by 17% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.